**Charity number: 1209730** 

## **PSORIATIC DISEASE UK** 

## **UNAUDITED** 

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 













## **PSORIATIC DISEASE UK** 

## **CONTENTS** 

||Page|
|---|---|
|**Reference and Administrative Details of the Charity, its Trustees and Advisers**|1|
|**Trustees' Report**|2 - 8|
|**Chairman's Statement**|9|
|**Statement of Financial Activities**|10|
|**Balance Sheet**|11|
|**Notes to the Financial Statements**|12 - 17|





## **PSORIATIC DISEASE UK** 

## **REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

|**Trustees**|J Nelson, Chair (appointed 23 August 2024)|
|---|---|
||A Davies (appointed 23 August 2024)|
||M Mayers (appointed 23 August 2024)|
||A Nelson (appointed 23 August 2024)|
||C Young (appointed 23 August 2024)|
|**Charity registered**<br>**number**<br>**Principal office**<br>**Accountants**|1209730<br>1 Miller Close<br>Hethersett<br>Norwich<br>NR9 3GD<br>BW Audit Ltd<br>Chartered Accountants<br>Berry & Warren<br>54 Thorpe Road<br>Norwich<br>NR1 1RY|



Page 1 



## **PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

The Trustees present their annual report together with the financial statements of the charity for the period 23 August 2024 to 30 November 2025. 

## **Objectives and activities** 

## **a. Policies and objectives** 

The objectives of the charity are to advance education and awareness for the public benefit throughout England and Wales of the impact of psoriatic disease by: 

- Promoting the value of lived experience, co-production and advocate for including the patient's voice in every aspect of healthcare provision; 

- Providing support, guidance and resources to patients and caregivers and promote the vital role both play in managing psoriatic disease; and 

- Relieving people impacted by the physical and mental burden of living with psoriatic disease and associated comorbidities by providing peer support and community networks for the public benefit. 

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit, including the guidance 'Public benefit: running a charity (PB2)'. 

## **b. Strategies for achieving objectives** 

To achieve its charitable objectives, Psoriatic Disease UK adopts a patient-centred approach focused on education, awareness, support, and community engagement. 

The charity seeks to: 

Increase public and professional understanding of psoriatic disease by developing and sharing accurate, evidence-based information and educational resources. 

- Amplify the voices and lived experiences of people affected by psoriatic disease to ensure that patient perspectives are represented in discussions relating to healthcare, research, policy, and service development. 

- Provide opportunities for peer support and community connection to help reduce isolation and improve wellbeing among individuals living with psoriatic disease and their families. 

- Collaborate with healthcare professionals, researchers, patient organisations, and other stakeholders to promote awareness, encourage knowledge sharing, and improve outcomes for those affected by psoriatic disease. 

- Use digital platforms, events, campaigns, and partnerships to reach wider audiences and increase awareness of the physical, emotional, and social impact of psoriatic disease. 

- Support the development of patient advocates and volunteers who can contribute to awareness raising, support activities, and the charity's wider mission. 

In implementing these strategies, the trustees regularly review activities, assess emerging needs within the psoriatic disease community, and ensure that the charity's resources are applied effectively to maximise public benefit and further its charitable purposes. 

Page 2 



**PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Objectives and activities (continued)** 

## **c. Activities undertaken to achieve objectives** 

During the year, Psoriatic Disease UK undertook a range of activities to advance its charitable objectives of increasing awareness and understanding of psoriatic disease, promoting the patient voice, and providing support to individuals and families affected by the condition. 

A key focus of the charity's work was the development and launch of Psoriatic Disease: 360, which was launched on 21 October 2025 in support of World Psoriasis Day. This comprehensive online resource was created to provide lived-experience perspectives on the physical, psychological, and social impacts of psoriatic disease. The project brought together patient experiences, educational content and practical information to help improve understanding of the condition among people living with psoriatic disease, their families, healthcare professionals and the wider public. 

The charity also established #TeamPSOR during the summer of 2025, creating a dedicated community for supporters, volunteers and fundraisers. Through this initiative, the charity sought to strengthen community involvement, encourage fundraising activity and provide additional opportunities for individuals to contribute to the charity's mission and objectives. 

Peer support remained a central part of the charity's activities. The charity continued to develop and moderate its Facebook Peer Support Group, originally launched alongside the charity in August 2024. The group provided a public platform for people affected by psoriatic disease to share experiences, discuss treatments, ask questions and offer mutual support. By encouraging open discussion of the realities of living with psoriatic disease, the group also supported wider awareness-raising and stigma reduction. 

To complement this offer, the charity launched PSOcial Space, a private Discord-based peer-support community, along with regular PSOcial Space Hangouts. These initiatives were designed to provide a safe and supportive environment where members could connect with others who share similar experiences, build supportive relationships and reduce feelings of isolation. 

The charity also engaged with national and international stakeholders to raise awareness of psoriatic disease and ensure that patient perspectives were represented in broader discussions on dermatology and patient advocacy. This included attendance at the GlobalSkin Conference in Prague, where the charity participated as the first UK psoriasis-focused member organisation and where the Chair contributed to conference discussions. The charity was also invited to participate at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, providing an opportunity to share the organisation's work and mission with healthcare professionals and the wider dermatology community. 

In addition to these specific initiatives, the charity continued to deliver awareness-raising and educational activities through its website, social media platforms and other digital communications, ensuring that people affected by psoriatic disease could access reliable information, support and opportunities for community engagement. 

The charity continued to develop its volunteer network and supporter engagement activities throughout the year. This included the introduction of a formal volunteer recruitment process, the establishment of fundraising opportunities through JustGiving, and the development of relationships with national and international stakeholder organisations. Following its admission as the first UK psoriasis-focused member of GlobalSkin in September 2024, the charity engaged with international patient advocacy networks to share learning and promote the experiences of people living with psoriatic disease in England and Wales. 

The trustees regularly reviewed the charity's activities throughout the year to ensure they remained aligned with its charitable objectives and responsive to the needs of the psoriatic disease community. 

Page 3 



**PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Objectives and activities (continued)** 

## **d. Main activities undertaken to further the charity's purposes for the public benefit** 

The trustees confirm that they have had regard to the Charity Commission's guidance on public benefit when planning and delivering the charity's activities. 

Psoriatic Disease UK exists to advance education and awareness of psoriatic disease, promote lived experience and patient voice, support people affected by the condition and their caregivers, and relieve the physical and mental burden associated with living with psoriatic disease through peer support and community networks. 

To further these purposes for the public benefit, the charity undertook a range of educational, awareness-raising and support activities throughout the year. 

The charity developed and launched Psoriatic Disease: 360, a comprehensive resource designed to improve understanding of the physical, psychological and social impacts of psoriatic disease. By providing accessible, evidence-based information alongside real-life experiences, the resource supports informed decision-making and increased awareness among patients, families, healthcare professionals and the wider public. 

The charity continued to provide peer support opportunities through its online communities, including its Facebook Peer Support Group and the newly established PSOcial Space Discord community and associated monthly Hangouts. These platforms enabled individuals affected by psoriatic disease to connect with others who share similar experiences, access practical and emotional support, reduce feelings of isolation and build supportive relationships. 

Through the creation of #TeamPSOR, the charity encouraged public participation in its activities, providing opportunities for supporters, volunteers, and fundraisers to help raise awareness of psoriatic disease and support the charity's work. 

The charity also engaged with healthcare professionals, patient organisations and advocacy groups at both national and international levels. Participation in the GlobalSkin Conference and the European Academy of Dermatology and Venereology (EADV) Congress 2025 enabled the charity to share patient perspectives, increase awareness of psoriatic disease and contribute to discussions aimed at improving understanding and support for people living with the condition. 

In addition, the charity continued to provide information and support through its website, social media channels, and digital communications. These resources were accessible to beneficiaries regardless of geographical location, helping to ensure that people affected by psoriatic disease could access information, support and opportunities for community engagement. 

The trustees believe that these activities have furthered the charity's purposes by increasing awareness and understanding of psoriatic disease, providing accessible peer support, amplifying patient voices and helping to reduce the physical, emotional and social burden experienced by people living with the condition. 

Page 4 



## **PSORIATIC DISEASE UK** 

**TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Achievements and performance** 

## **a. Main achievements of the charity** 

During its first reporting period, from its establishment in August 2024 to 30 November 2025, Psoriatic Disease UK made significant progress in developing its support services, public profile, volunteer community and national and international relationships. 

A principal achievement was the development of accessible online peer-support opportunities for people affected by psoriasis, psoriatic arthritis and associated conditions. The charity continued to develop and moderate its Facebook Peer Support Group, creating opportunities for members to share experiences, ask questions and offer mutual support. The group�s lived-experience discussions also helped the charity remain informed about the concerns and priorities of the community it serves. 

The charity broadened its peer-support provision through the creation of PSOcial Space, its private Discord community. To make the platform more accessible to people unfamiliar with Discord, the charity produced a step-by-step user guide. This was followed by the introduction of monthly PSOcial Space Hangouts starting in March 2025, providing regular opportunities for participants to connect, discuss relevant subjects, and build supportive relationships. 

The charity also made progress in raising awareness of the wider physical, psychological and social effects of psoriatic disease. In October 2024, it delivered the first PSOR Social, an online awareness and fundraising event designed to encourage open conversation about psoriasis, psoriatic arthritis, caregiving, mental wellbeing and the importance of peer support. 

For World Psoriasis Day 2025, the charity launched Psoriatic Disease: 360, an ongoing lived-experience awareness project. The initiative invited patients, caregivers, family members and healthcare professionals to contribute short perspectives about the realities of psoriatic disease, including diagnosis, treatment, stigma, mental health, employment and relationships. This provided a structured means through which the charity could amplify diverse experiences and challenge narrow perceptions of the condition. 

The charity strengthened its base of supporters and volunteers during the period. It established a presence on JustGiving, introduced a more formal volunteer recruitment pathway, and launched #TeamPSOR as a shared identity for volunteers, advocates, supporters and fundraisers. The launch was supported by participation in Run Norwich 2025, where three supporters ran in aid of the charity, and representatives distributed information to the crowds to raise public awareness. 

An important organisational achievement was the establishment of Psoriatic Disease UK�s first international partnership. In September 2024, the charity became a member of the International Alliance of Dermatology Patient Organisations, known as GlobalSkin, becoming its first UK member organisation representing psoriasis. This was followed by attendance at the GlobalSkin Conference in Prague in April 2025, where the charity represented people affected by psoriatic disease in England and Wales, presented its developing support offering and built relationships with international patient organisations. The charity�s Chair also contributed to the event and was shortlisted for a Patient Leader Award in recognition of creative expression of lived experience. 

The charity further increased its visibility within the international dermatology community by participating in the European Academy of Dermatology and Venereology Congress 2025 in Paris. This enabled Psoriatic Disease UK to present its patient-led mission and support activities to healthcare professionals, researchers and other dermatology stakeholders. 

Throughout the reporting period, the charity also used its website, social media channels, community discussions, and personal stories to increase understanding of psoriatic disease, promote lived experience, and signpost people to support. These activities provided a foundation from which the charity could continue developing its educational, awareness and peer-support work after the end of the reporting period. 

Page 5 



**PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Achievements and performance (continued)** 

The trustees consider that these achievements demonstrate meaningful progress during the charity�s first reporting period in establishing accessible peer-support communities, amplifying patient and caregiver voices, increasing public and professional awareness, developing volunteer participation and representing the psoriatic disease community nationally and internationally. 

## **b. Plans for Future Periods** 

In the next reporting period, the trustees intend to consolidate the charity�s foundations while continuing to develop its educational, awareness-raising and peer-support activities. 

The charity plans to maintain and develop Psoriatic Disease: 360, strengthen its peer-support communities, and continue the monthly PSOcial Space Hangouts. It will seek to develop #TeamPSOR by creating further opportunities for volunteering, community fundraising and public participation. 

Psoriatic Disease UK also intends to build upon the relationships established through GlobalSkin, EADV and other healthcare and patient organisations. These relationships will support the charity�s aim of amplifying lived experience and improving professional and public understanding of psoriatic disease. 

The trustees will continue to review the charity�s organisational capacity, funding position, safeguarding arrangements, digital infrastructure, and volunteer support to ensure that future growth remains sustainable and centred on beneficiaries' needs. 

## **Financial review** 

## **a. Going concern** 

After making appropriate enquiries, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements. Further details regarding the adoption of the going concern basis can be found in the accounting policies. 

## **b. Reserves policy** 

The Board of Trustees has agreed that the ideal target for our unrestricted financial reserves is £1,000. 

This level has been calculated to provide a sufficient safety net to cover our core operational costs for several months in the event of a funding shortfall, allowing time to source alternative funding. Specifically, this £1,000 buffer ensures that our essential digital infrastructure (including our website, email, support groups, communication channels, and reporting tools) remains online and covers vital administrative costs such as our accounting software subscription and charity mobile phone line. 

As a growing patient-led charity currently investing our income directly into community projects and support, our free reserves at 30 November 2025 are £1,050. To maintain this target, the Trustees are actively designating a percentage of general, unrestricted donations to the reserves balance and continuing to promote community fundraising events to generate unrestricted income. Unrestricted funds at 30 November 2025 were £1,192. 

Page 6 



**PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Structure, governance and management** 

## **a. Constitution** 

Psoriatic Disease UK is a Charitable Incorporated Organisation registered in England and Wales with charity number 1209730. The charity was registered on 23 August 2024 and is governed by its constitution. 

## **b. Methods of appointment or election of Trustees** 

The management of the charity is the responsibility of the Trustees. Trustees are appointed in accordance with the provisions of the charity�s constitution. 

## **c. Organisational structure and decision-making policies** 

The Board of Trustees is responsible for the charity�s governance, strategic direction, financial oversight and compliance with its legal and regulatory obligations. The trustees meet regularly to review the charity�s activities, finances, risks and future priorities. Significant decisions are made collectively and recorded in the minutes of trustee meetings. 

The charity is operated principally through the contribution of trustees and volunteers. Day-to-day activities may be allocated to individual trustees or volunteers according to their skills and experience, with the Board retaining overall responsibility and oversight. 

## **d. Policies adopted for the induction and training of Trustees** 

New trustees receive information about the charity�s constitution, charitable purposes, current activities, finances, key policies and relevant Charity Commission guidance. Trustees are encouraged to identify further training or guidance required to support them in carrying out their duties. 

## **e. Risk management** 

The trustees regularly consider the principal risks facing the charity and the measures required to manage them. During the period, key areas of oversight included financial sustainability, safeguarding and moderation within online communities, data protection, the accuracy of published health information, continuity of digital services, volunteer capacity, cyber security and reputational risk. 

The charity manages these risks through trustee oversight, moderation arrangements, appropriate policies and procedures, controlled access to digital systems, financial monitoring and regular review of activities and community needs. The trustees recognise that risk management is an ongoing process and will continue to strengthen the charity�s controls as its services and community develop. The trustees review these risks on an ongoing basis and implement proportionate controls to reduce the likelihood and impact of identified risks. 

## **f. Fundraising** 

The charity undertook community fundraising through supporters and online platforms during the period without the use of any professional fundraiser or commercial participant. Fundraising activity was overseen by the trustees and was intended to be open, honest and respectful. No fundraising complaints were received for this period. 

Page 7 



## **PSORIATIC DISEASE UK** 

## **TRUSTEES' REPORT (CONTINUED) FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **Structure, governance and management (continued)** 

## **g. Safeguarding, Serious Incidents and Conflicts** 

No safeguarding, serious incidents or trustee conflicts were reported for this period. 

## **Statement of Trustees' responsibilities** 

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice). 

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; observe the methods and principles of the Charities SORP (FRS 102); make judgments and accounting estimates that are reasonable and prudent; 

- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

Approved by order of the members of the board of Trustees and signed on their behalf by: 


**J Nelson** (Chair of Trustees) Date: 18th September 2026 

Page 8 



## **PSORIATIC DISEASE UK** 

## **CHARTERED ACCOUNTANT'S REPORT TO THE TRUSTEES ON THE PREPARATION OF THE UNAUDITED FINANCIAL STATEMENTS OF PSORIATIC DISEASE UK FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

In order to assist you to fulfil your duties under the Charities Act 2011, we have prepared for your approval the financial statements of Psoriatic Disease UK for the period ended 30 November 2025 which comprise the Statement of financial activities, the Statement of financial position and the related notes from the accounting records and from information and explanations you have given to us. 

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://icaew.com/regulation. 

This report is made solely to the Trustees, as a body, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for your approval the financial statements of Psoriatic Disease UK and state those matters that we have agreed to state to the Trustees, as a body, in this report in accordance with ICAEW Technical release TECH07/16AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Psoriatic Disease UK and its Trustees, as a body, for our work or for this report. 

It is your duty to ensure that Psoriatic Disease UK has kept adequate accounting records and to prepare financial statements that give a true and fair view of the assets, liabilities, financial position and net resources expended of Psoriatic Disease UK. You consider that Psoriatic Disease UK is exempt from the statutory audit requirement for the year. 

We have not been instructed to carry out an audit or review of the financial statements of Psoriatic Disease UK. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the financial statements. 


................................................ BW Audit Ltd Chartered Accountants 54 Thorpe Road Norwich NR1 1RY 

Date: 24 September 2026 

Page 9 



## **PSORIATIC DISEASE UK** 

## **STATEMENT OF FINANCIAL ACTIVITIES FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

|**Note**<br>**Income from:**<br>Donations and legacies<br>3<br>**Total income**<br>**Expenditure on:**<br>Charitable activities<br>**Total expenditure**<br>**Net movement in funds**<br>**Reconciliation of funds:**<br>Net movement in funds<br>**Total funds carried forward**|**Unrestricted**<br>**funds**<br>**2025**<br>**£**<br>**3,433**<br>**3,433**<br>**2,241**<br>**2,241**<br>**1,192**<br>**1,192**<br>**1,192**|**Restricted**<br>**funds**<br>**2025**<br>**£**<br>**911**<br>**911**<br>**911**<br>**911**<br>**-**<br>**-**<br>**-**|**Total**<br>**funds**<br>**2025**<br>**£**<br>**4,344**<br>**4,344**|
|---|---|---|---|
||||**3,152**<br>**3,152**|
||||**1,192**|
||||**1,192**<br>**1,192**|



The Statement of Financial Activities includes all gains and losses recognised in the period. 

The notes on pages 12 to 17 form part of these financial statements. 

Page 10 



## **PSORIATIC DISEASE UK** 

## **BALANCE SHEET AS AT 30 NOVEMBER 2025** 

|**Note**<br>**Fixed assets**<br>Tangible assets<br>6<br>**Current assets**<br>Cash at bank and in hand<br>**Current liabilities**<br>Creditors: amounts falling due within one year<br>7<br>**Net current assets**<br>**Total assets less current liabilities**<br>**Total net assets**<br>**Charity funds**<br>Restricted funds<br>8<br>Unrestricted funds<br>8<br>**Total funds**|**1,650**<br>**1,650**<br>**(600)**|**2025**<br>**£**<br>**142**|
|---|---|---|
|||**142**<br>**1,050**|
|||**1,192**|
||||
|||**1,192**|
|||**-**<br>**1,192**|
||||
|||**1,192**|



The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by: 


**J Nelson** (Chair of Trustees) Date: 18th September 2026 

The notes on pages 12 to 17 form part of these financial statements. 

Page 11 



## **PSORIATIC DISEASE UK** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **1. General information** 

Psoriatic Disease UK is a charity registered as a CIO in England and Wales. The registered office is 1 Miller Close, Hethersett, Norwich NR9 3GD. The registered number of the charity is 1209730. 

## **2. Accounting policies** 

## **2.1 Basis of preparation of financial statements** 

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011. 

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn. 

Psoriatic Disease UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy. 

## **2.2 Income** 

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. 

Grants are included in the Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in the relevant funds on the Balance Sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued. 

## **2.3 Expenditure** 

Expenditure is recognised on an accruals basis once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. 

Expenditure on charitable activities is incurred on directly undertaking the activities which further the charity's objectives, as well as any associated support costs. 

All expenditure is inclusive of irrecoverable VAT. 

Page 12 



**PSORIATIC DISEASE UK** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **2. Accounting policies (continued)** 

## **2.4 Tangible fixed assets and depreciation** 

Tangible fixed assets costing £100 or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably. 

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost. 

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method. 

Depreciation is provided on the following basis: 

- Computer equipment 3 years 

## **2.5 Cash at bank and in hand** 

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account. 

## **2.6 Liabilities and provisions** 

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. 

Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. 

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of Financial Activities as a finance cost. 

## **2.7 Financial instruments** 

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. 

Page 13 



## **PSORIATIC DISEASE UK** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **2. Accounting policies (continued)** 

## **2.8 Fund accounting** 

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes. 

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements. 

## **3. Income from donations and legacies** 

|Donations<br>Grants|**Unrestricted**<br>**funds**<br>**2025**<br>**£**<br>3,433<br>-<br>3,433|**Restricted**<br>**funds**<br>**2025**<br>**£**<br>-<br>911<br>911|**Total**<br>**funds**<br>**2025**<br>**£**<br>**3,433**<br>**911**<br>**4,344**|
|---|---|---|---|



## **4. Analysis of expenditure by activities** 

||**Activities**|||
|---|---|---|---|
||**undertaken**|**Support**|**Total**|
||**directly**|**costs**|**funds**|
||**2025**|**2025**|**2025**|
||**£**|**£**|**£**|
|Charitable activities|1,537|1,615|**3,152**|



Page 14 



## **PSORIATIC DISEASE UK** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **4. Analysis of expenditure by activities (continued)** 

## **Analysis of direct costs** 

|Travel and accommodation<br>Website<br>**Analysis of support costs**<br>Advertising and marketing<br>Postage and stationery<br>Telephone<br>Accountancy fees|**Charitable**<br>**activities**<br>**2025**<br>**£**<br>1,219<br>318<br>1,537<br>**Charitable**<br>**activities**<br>**2025**<br>**£**<br>856<br>129<br>30<br>600<br>1,615|**Total**<br>**funds**<br>**2025**<br>**£**<br>**1,219**<br>**318**<br>**1,537**|
|---|---|---|
|||**Total**<br>**funds**<br>**2025**<br>**£**<br>**856**<br>**129**<br>**30**<br>**600**<br>**1,615**|



## **5. Trustees' remuneration and expenses** 

During the period, no Trustees received any remuneration or other benefits. 

During the period ended 30 November 2025, no Trustee expenses have been incurred. 

Page 15 



## **PSORIATIC DISEASE UK** 

|**NOTES TO THE FINANCIAL STATEMENTS**<br>**FOR THE PERIOD ENDED 30 NOVEMBER 2025**||
|---|---|
|**6.**<br>**Tangible fixed assets**<br>**Cost or valuation**<br>Additions<br>At 30 November 2025<br>**Net book value**<br>At 30 November 2025<br>**7.**<br>**Creditors: Amounts falling due within one year**<br>Accruals and deferred income|**Computer**<br>**equipment**<br>**£**<br>**142**<br>**142**<br>**142**<br>**2025**<br>**£**<br>**600**|



Page 16 



## **PSORIATIC DISEASE UK** 

## **NOTES TO THE FINANCIAL STATEMENTS FOR THE PERIOD ENDED 30 NOVEMBER 2025** 

## **8. Statement of funds** 

## **Statement of funds - current period** 

|**Unrestricted funds**<br>General Funds<br>**Restricted funds**<br>IADPO travel grants<br>**Total of funds**|**Income**<br>**£**<br>**3,433**<br>**911**<br>**4,344**|**Expenditure**<br>**£**<br>**(2,241)**<br>**(911)**<br>**(3,152)**|**Balance at**<br>**30**<br>**November**<br>**2025**<br>**£**<br>**1,192**|
|---|---|---|---|
||||**-**|
||||**1,192**|



IADPO travel grants have been provided to support the cost of travelling to Global Skin events. 

## **9. Analysis of net assets between funds** 

## **Analysis of net assets between funds - current period** 

|Tangible fixed assets<br>Current assets<br>Creditors due within one year<br>**Total**|**Unrestricte**<br>**d funds**<br>**2025**<br>**£**<br>142<br>1,650<br>(600)<br>1,192|**Total**<br>**funds**<br>**2025**<br>**£**<br>**142**<br>**1,650**<br>**(600)**<br>**1,192**|
|---|---|---|



## **10. Related party transactions** 

The charity has not entered into any related party transaction during the period, nor are there any outstanding balances owing between related parties and the charity at 30 November 2025. 

Page 17 

